News & Updates
Filter by Specialty:
Brensocatib has no impact on COVID-19 clinical outcomes
Results of the STOP-COVID trial, presented at ERS 2022, showed no clinical outcome benefit with the dipeptidyl peptidase-1 (DPP-1) inhibitor brensocatib compared with placebo in patients hospitalized with COVID-19 in the UK.
Brensocatib has no impact on COVID-19 clinical outcomes
02 Oct 2022
Pemafibrate superior to conventional fibrates in T2DM
Treatment with pemafibrate in patients with type 2 diabetes mellitus (T2DM) yields more favourable effects on lipid profile, as well renal function, as compared with conventional fibrates, a study has found.
Pemafibrate superior to conventional fibrates in T2DM
01 Oct 2022
Brolucizumab for neovascular age-related macular degeneration holds up in real world
The use of brolucizumab for the treatment of patients with neovascular age-related macular degeneration (nAMD) in the real-world setting appears to be effective and safe, consistent with data from pivotal trials, as reported in a study.
Brolucizumab for neovascular age-related macular degeneration holds up in real world
30 Sep 2022
Add-on, switch-to PEG-IFN therapy strategies improve serological response in CHB patients
Chronic hepatitis B (CHB) patients, who have virological response with long-term entecavir (ETV) treatment, appear to fare well with a strategy of adding or switching to peginterferon (PEG-IFN) therapy, as shown in a study.
Add-on, switch-to PEG-IFN therapy strategies improve serological response in CHB patients
30 Sep 2022
SGLT2 inhibitors potentially protective against dry eye disease
Type 2 diabetes (T2D) patients on sodium-glucose cotransporter 2 (SGLT2) inhibitors appear to be at lower risk of dry eye disease (DED) compared with their counterparts who are receiving glucagonlike peptide-1 receptor agonists (GLP-1 RAs), as shown in a study.
SGLT2 inhibitors potentially protective against dry eye disease
29 Sep 2022
Apixaban better than enoxaparin for extended-duration VTE prophylaxis after surgery
Apixaban is not inferior to enoxaparin for extended-duration venous thromboembolic event (VTE) prophylaxis (EP) following urologic oncology surgery, reveals a study. In addition, apixaban is associated with fewer major complications and compliance-related adverse events.